

Cannabinoquinones

Subjects: Biology

Contributor: Giovanni Appendino

Cannabinoquinones are highly electrophilic compounds and undergo non-transient thia-Michael addition when assayed in the cysteamine assay. With 2-substituted compounds, the assay was complicated by the interaction of the amino group of cysteamine with the quinone carbonyl, resulting in a change of the DMSO spectrum upon cysteamine addition, presumably due to the transient Schiff base formation.

Keywords: cannabinoids ; quinones ; oxidation ; thia-Michael addition ; immunomodulation ; scleroderma

1. Introduction

Phytocannabinoids are endogenously produced by *Cannabis sativa* L. in an acidic form, a discovery reported by Krejčí and Šantavý [1] five decades after the seminal purification of cannabiol (CBN, **Figure 1**, 1) from hashish in 1899 [2]. Exogenous factors (heat, light, oxygen) are next responsible for the non-enzymatic expansion of the diversity of the native phytocannabinoid pool [3]. Neutral cannabinoids are generated by decarboxylation of their acidic precursors, a reaction dependent on the presence of a mesomerically electron-donating para -oxygen atom [4], while atmospheric oxidation can affect both the terpenyl residue, as shown by the aromatization of Δ^9 - and Δ^8 -tetrahydrocannabinols [Δ^9 - and Δ^8 - THC (2, 3, respectively) to cannabiol (1) [3], and the resorcinylic core, generating colored quinones [5]. Air oxidation of resorcinylic phytocannabinoids is relatively slow, at least in the plant material and in the solid state, and cannabinoquinones are susceptible to further oxidation and degradation. Compounds of this type have, therefore, only been isolated as trace constituents of *C. sativa* extracts [3]. Nevertheless, they have played an important role in the history of Cannabis, since their formation provided the basis for the Beam test, the first forensic color assay for hashish [6], and giving a reddish hue to the high vacuum Cannabis distillates (red oils) from which the first phytocannabinoids were isolated and characterized [7]. The lack of narcotic activity of acidic cannabinoids, biogenetically derived from cannabigerolic acid (CBGA, 4), and of cannabinoquinones, has long been reductively equated to a lack of bioactivity. This and instability issues have combined to delay systematic studies in the area, but significant clinical potential has now emerged for both classes of compounds, and especially cannabinoquinones. Thus, the aminocannabinoquinone VCE-004.8 (5) is currently in phase 2 clinical studies with orphan drug status in the EU and USA for the treatment of diffuse cutaneous systemic sclerosis [8]; its analogue VCE-003.2 (6) has completed pre-clinical investigation [9], receiving orphan drug designation by the EMA and FDA for the management of Huntington's disease, and interest in the anticancer activity of cannabinoquinones has been revamped by recent studies [10].




Figure 1. Structure of CBN (1), Δ^9 -THC (2), Δ^8 -THC (3), cannabigerolic acid (CBGA, 4), VCE-004.8 (5) and VCE 003.2 (6).

2. Synthesis and Chemistry of Cannabinoquinoids

The formation of cannabinoquinones under non-radical conditions was first reported by Mechoulam, who discovered that the λ 3-periodinane bis(trifluoroacetoxy)iodobenzene (BTIP, PIFA) could convert Δ 8-THC (3) into the quinone 12 [11]. The reaction involves formation of an iodonium (III) intermediate, that next undergoes nucleophilic attack by an external water molecule to the para -position, less encumbered compared to the ortho -positions. Elimination of iodobenzene eventually generates a p -quinone in yields between 31% and 50% (Scheme 3).

Unexpectedly, oxidation of the monophenolic phytocannabinoid cannabichromene (CBC, 42) afforded a p -quinone (44) also with SIBX [12], presumably because of electrocyclic opening of the chromene ring of an originally generated o -quinone (43) to a cyclohexenone (44), that by a series of keto-enolic tautomerization steps undergoes electrocyclization aromatization to a p -quinone (Scheme 5) [13].

Acidic cannabinoids are stable under Beam-conditions, and did not afford quinones upon reaction with SIBX, that, just like the Beam biphasic system [9], could oxidize 2-alkyl substituted cannabinoids to their corresponding quinones. Taken together, the results of these synthetic studies have established iodanes as the oxidants of choice for the generation of cannabinoquinones from phytocannabinoids. The λ 5-iodane SIBX can be used for diphenolic substrates, while the λ 3-iodane PIFA is required for monophenolic phytocannabinoids, with the notable exception of chromenic substrates, where valence equilibration converts o -quinones into p -quinones [12]. The dimerization that plagues the autoxidative reactions is not observed with iodane oxidants, and any potential issue of metal retention by chelation is also prevented. The iodine oxidation of resorcinolic cannabinoids could be scaled-up to gram-levels [5], and proved suitable for the GMP-production of the amounts of VCE-004.8 required for the phase 1 clinical studies [14].

Cannabinoquinones are highly electrophilic compounds and undergo non-transient thia-Michael addition when assayed in the cysteamine assay (Scheme 7) [15]. With 2-substituted compounds, the assay was complicated by the interaction of the amino group of cysteamine with the quinone carbonyl, resulting in a change of the DMSO spectrum upon cysteamine addition, presumably due to the transient Schiff base formation. This resulted in chemical shift changes, with no evidence, however, of thiol addition [15]. Phase switch to CDCl_3 or extraction with hexane regenerated the starting compound, showing that the introduction of a substituent at the 2-position quenches Michael reactivity, an observation of relevance for the bioactivity profile of cannabinoquinones (see Section 5.1).

3. Spectroscopic Properties of Cannabinoquinones

Parallel to the color development, NMR spectroscopy can be an efficient system to detect and monitor the conversion of phytocannabinoids into the corresponding monomeric quinones. ^1H NMR spectra of p -cannabinoquinones are characterized by the obvious loss of one of the two resorcinyl protons, with the remaining signal experiencing a downfield shift of ab. 0.2–0.3 ppm (Figure 2) [5]. The hallmark of p -cannabinoquinones ^{13}C NMR spectra is the presence of the two carbonyl resonances around δ C 180–190 ppm. The third oxygen-bearing carbon of the same ring resonates at $\sim\delta$ C 150 ppm, while the single methine experiences a marked downfield shift to $\sim\delta$ C 130 ppm [5][12].




Figure 2. Top: Comparison of selected ^1H (black) and ^{13}C (red) NMR resonances of a phytocannabinoid (CBG, A) with those of the corresponding quinone (B). Bottom: Comparison of selected ^1H (black) and ^{13}C (red) NMR resonances of O-methyl-p-CBDQ (C) and O-methyl-o-CBDQ (D).

As described in Section 3.2.2, a different order in the methylation/oxidation sequence can provide alternative ortho- and para-O-methylcannabiniquinones, providing the opportunity of a vis-à-vis spectroscopic comparison between isomeric quinoids. As shown in **Figure 2**, the single proton signal of the quinone ring is markedly downfield shifted ($\Delta\delta$ ab. 0.4 ppm) in o-cannabiniquinones and other diagnostic differences are also present in the ^{13}C NMR spectra. Indeed, the ortho-isomer can be easily identified, since the couple of carbonyl signals resonates at significantly lower ppm values compared to the para-one (δ C 175–180 vs. δ C 185–190) [13]. Both this high-field shift and the higher resonance values of the -OMe-bearing carbon can be explained by considering that an ortho-quinone carbonyl is a better electron sink than a para-quinone carbonyl for the mesomeric delocalization of the lone pair of the methoxy oxygen. Thus, due to a more extended conjugation, the contribution of the zwitterionic resonance form that includes a methoxonium ion is larger in ortho-cannabiniquinones compared to para-cannabiniquinones.

4. Bioactivity Studies

Taken together, these studies show that cannabiniquinones are interesting structures for the development of novel anticancer agents, but the stability in solution of the lead compound of the class (CBDQ, HU-331, 9) seems too limited for further developments. In addition, the mechanism of activity needs additional investigation, while the pharmacokinetic profile of these compounds is still unknown.

Interest in cannabiniquinones in the neuro-immunological area was spurred by considerations of the biological profile of CBD (7). This compound has a multitude of low-affinity targets that includes GPCR, ion channels, enzymes, and transcription factors of critical relevance for neuroprotection and immunity [16]. The twisted bicyclic structural element of CBD seems to have an inherent, broadly tuned complementarity for biological surfaces, possibly expressed by different torsion angles along the methyl-aryl atropisomeric axis, unable, however, to engage the compound in tight intermolecular interactions. In this context, the increased polarization associated to the resorcinol-to-hydroxyquinone oxidation is expected to strengthen electrostatic and hydrogen bonding interactions with macromolecular targets, additionally increasing biological “stickiness” by metal chelation, covalent reactivity via Michael addition and involvement in redox cycles. This strategy was confirmed by comparison of the PPAR- γ modulation activity of cannabidiol (CBD) and its corresponding quinone (CBDQ). While the former showed only marginal activity in the assay ($\text{EC}_{50} > 25 \mu\text{M}$), the latter was endowed with potent activity ($\text{EC}_{50} = 10.5 \mu\text{M}$), further increased by one order of magnitude by the aza-Michael adducts [8]. These observations were duplicated with the quinones of cannabigerol (CBG, 13) and CBC (42) [9], suggesting a class-specific trend, that led to extensive studies and to the selection of two candidates for systematic studies.

The CBG-derived amino-hydroxyquinone 6 (VCE-003.2) showed potent agonistic activity at PPAR- γ ($\text{IC}_{50} = 1.2 \mu\text{M}$), binding both the canonical and the alternative binding sites of the transcription factor, and lacking activity on cannabinoid receptors [17]. In BV2 mice microglia- and astrocytes cells, 6 could inhibit the secretion of various soluble pro-inflammatory mediators (IL-6, TNF- α , IL-1b) at one-digit μM concentration, reducing the expression of iNOS in BV2 microglia cells in a way that is sensitive to PPAR- γ (GW9662) antagonists [17]. When orally or intraperitoneally administered, 6 showed beneficial effects in murine models of Huntington's disease [9][18], Parkinson's disease [17][19], and amyotrophic lateral sclerosis [20]. Compound 6, formulated as EHP-102, has completed preclinical development and is entering a phase 1 study for Huntington's disease and Parkinson's disease, with orphan drug status in the EU and USA for the former condition [21].

Within the aminoquinones derived from CBD (7), the benzylamine adduct 5 emerged as a powerful activator of the PPAR- γ transcriptional activity [8] and, of the hypoxia inducible factor (HIF-1) pathway, an activity resulting from inhibition of prolyl hydroxylases [22]. This aminoquinone 5 (VCE-004.8) was neutral at CB 1 but behaved as an activator at CB 2 [8], and was a partial PPAR- γ activator, devoid of adipogenic activity. In a murine model of metabolic syndrome (high-fat diet), 5 could reduce the metabolic disruption and inflammation associated to this condition, promoting weight loss, and reducing total fat mass, adipocyte volume, and plasma triglycerides [23]. Remarkably, it could also increase FGF21 mRNA expression in white and brown adipose cells, as well as in a BAT cell, significantly ameliorating glucose tolerance, reducing leptin levels and increasing adiponectin and incretins (GLP-1, GIP) levels [23]. VCE-004.8 (5) showed anti-fibrotic activity in a murine scleroderma model as well as in different multiple sclerosis models, preventing immune cell infiltration, demyelination, and axonal damage [24]. Its oral formulation (EHP-101) has completed a Phase 1 study on over 100 healthy volunteers, demonstrating excellent safety and tolerability, and is proceeding now, under orphan drug status by EMA in Europe and FDA in USA, to a Phase 2 clinical study for the management of scleroderma [25].

References

1. Krejčí, Z.; Šantavý, F. Isolace Dalších Látek z Listů Indického Konopi *Cannabis sativa* L. [Isolation of Other Substances from the Leaves of the Indian Hemp *Cannabis sativa* L.]. *Acta Univ Palacki Olomuc* 1955, 6, 59–66.
2. Wood, T.B.; Spivey, W.T.N.; Easterfield, T.H. Cannabinol, Part I. *J. Chem. Soc.* 1899, 75, 20–36.
3. Hanuš, L.O.; Meyer, S.M.; Muñoz, E.; Tagliatalata-Scafati, O.; Appendino, G. Phytocannabinoids: A Unified Critical Inventory. *Nat. Prod. Rep.* 2016, 33, 1357–1392.
4. Pollastro, F.; De Petrocellis, L.; Schiano-Moriello, A.; Chianese, G.; Heyman, H.; Appendino, G.; Tagliatalata-Scafati, O. Reprint of: Amorfrutin-type phytocannabinoids from *Helichrysum umbraculigerum*. *Fitoterapia* 2018, 126, 35–39.
5. Caprioglio, D.; Mattoteia, D.; Pollastro, F.; Negri, R.; Lopatriello, A.; Chianese, G.; Minassi, A.; Collado, J.A.; Munoz, E.; Tagliatalata-Scafati, O.; et al. The Oxidation of Phytocannabinoids to Cannabinoquinoids. *J. Nat. Prod.* 2020, 83, 1711–1715.
6. Beam, W. Fourth Report Wellcome Tropical Research Lab. *Chem. Sect. Rep. Sudan Gov.* 1911, 25, 105.
7. Appendino, G. The early history of cannabinoid research. *Rend. Lincei. Sci. Fis. Nat.* 2020, 31, 919–929.
8. del Río, C.; Navarrete, C.; Collado, J.A.; Bellido, M.L.; Gómez-Cañas, M.; Pazos, M.R.; Fernández-Ruiz, J.; Pollastro, F.; Appendino, G.; Calzado, M.A.; et al. The Cannabinoid Quinol VCE-004.8 Alleviates Bleomycin-induced Scleroderma and Exerts Potent Antifibrotic Effects Through Peroxisome Proliferator-Activated Receptor- γ and CB2 Pathways. *Sci. Rep.* 2016, 6, 21703.
9. Díaz-Alonso, J.; Paraíso-Luna, J.; Navarrete, C.; Del Río, C.; Cantarero, I.; Palomares, B.; Agualeles, J.; Fernández-Ruiz, J.; Bellido, M.L.; Pollastro, F.; et al. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. *Sci. Rep.* 2016, 6, 29789.
10. Kogan, N.M.; Peters, M.; Mechoulam, R. Cannabinoid Quinones—A Review and Novel Observations. *Molecules* 2021, 26, 1761.
11. Kogan, N.M.; Rabinowitz, R.; Levi, P.; Gibson, D.; Sandor, P.; Schlesinger, M.; Mechoulam, R. Synthesis and Antitumor Activity of Quinonoid Derivatives of Cannabinoids. *J. Med. Chem.* 2004, 47, 3800–3806.
12. Mattoteia, D.; Tagliatalata-Scafati, O.; Muñoz, E.; de la Vega, L.; Caprioglio, D.; Appendino, G. Regiodivergent Synthesis of ortho- and para-Cannabinoquinones. *Eur. J. Org. Chem.* 2020, 2020, 7429–7434.
13. Caprioglio, D.; Mattoteia, D.; Minassi, A.; Pollastro, F.; Lopatriello, A.; Muñoz, E.; Tagliatalata-Scafati, O.; Appendino, G. One-Pot Total Synthesis of Cannabinol via Iodine-Mediated Deconstructive Annulation. *Org. Lett.* 2019, 21, 6122–6125.
14. Appendino, G. Unpublished Work; Muñoz, E., Ed.; University of Eastern Piedmont: Vercelli, Italy, 2021.
15. Caprioglio, D.; Minassi, A.; Avonto, C.; Tagliatalata-Scafati, O.; Appendino, G. Thiol-trapping natural products under the lens of the cysteamine assay: Friends, foes, or simply alternatively reversible ligands? *Phytochem. Rev.* 2020, 19, 1307–1321.
16. Nelson, K.M.; Bisson, J.; Singh, G.; Graham, J.G.; Chen, S.-N.; Friesen, J.B.; Dahlin, J.L.; Niemitz, M.; Walters, M.A.; Pauli, G.F. The Essential Medicinal Chemistry of Cannabidiol (CBD). *J. Med. Chem.* 2020, 63, 12137–12155.
17. García, C.; Gómez-Cañas, M.; Burgaz, S.; Palomares, B.; Gómez-Gálvez, Y.; Palomo-Garo, C.; Campo, S.; Ferrer-Hernández, J.; Pavicic, C.; Navarrete, C.; et al. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPAR γ receptor. *J. Neuroinflammation* 2018, 15, 19.
18. Agualeles, J.; Paraíso-Luna, J.; Palomares, B.; Bajo-Grañeras, R.; Navarrete, C.M.; Ruiz-Calvo, A.; García-Rincón, D.; García-Taboada, E.; Guzmán, M.; Muñoz, E.; et al. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. *Transl. Neurodegener.* 2019, 8, 9.
19. Burgaz, S.; García, C.; Gómez-Cañas, M.; Muñoz, E.; Fernández-Ruiz, J. Development of An Oral Treatment with the PPAR- γ -Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease. *Molecules* 2019, 24, 2702.
20. Cueto, C.R.; Santos-García, I.; García-Toscano, L.; Espejo-Porras, F.; Bellido, M.; Fernández-Ruiz, J.; Muñoz, E.; de Lago, E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. *Biochem. Pharmacol.* 2018, 157, 217–226.
21. Available online: <https://emeraldpharma.life/pipeline/> (accessed on 22 May 2021).
22. Navarrete, C.; Carrillo-Salinas, F.; Palomares, B.; Mecha, M.; Jiménez-Jiménez, C.; Mestre, L.; Feliú, A.; Bellido, M.L.; Fiebich, B.L.; Appendino, G.; et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative:

Implications for multiple sclerosis therapy. *J. Neuroinflammation* 2018, 15, 64.

23. Palomares, B.; Ruiz-Pino, F.; Navarrete, C.M.; Velasco, I.; Sánchez-Garrido, M.A.; Jimenez-Jimenez, C.; Pavicic, C.; Vazquez, M.J.; Appendino, G.; Bellido, M.L.; et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. *Sci. Rep.* 2018, 8, 16092.
24. Navarrete, C.; García-Martin, A.; Garrido-Rodriguez, M.; Mestre, L.; Feliú, A.; Guaza, C.; Calzado, M.A.; Muñoz, E. Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis. *Neurobiol. Dis.* 2020, 143, 104994.
25. Available online: <https://emeraldpharma.life/ehp-101/> (accessed on 30 June 2021).

Retrieved from <https://encyclopedia.pub/entry/history/show/30463>